Bionime leading IoMT Trends of the Future on Spotlight at Düsseldorf Medical Fair 2022

Bionime leading IoMT Trends of the Future on Spotlight at Düsseldorf Medical Fair 2022

Taiwan – October 24, 2022 —

Bionime, a Taiwanese leading designer and manufacturer of blood glucose monitoring (BGM) devices, will participate a leading medical trade fair at Düsseldorf of MEDICA 2022. An integrated part of the trade fair, will from 14 to 17 November once more offer an overview of top trends in data-driven medicine.

As the pandemic has highlighted the importance of Medical Things (IoMT) utilization in the medical institution, it has driven more medical equipment manufacturing companies to accelerate their technical innovations to connect their product with related software. Rightest iFree CGM App, which won the Taiwanese Excellence Award in 2019 is a technology application that provides a total solution for diabetes management in the palm of patients’ hands.

Patients can easily transfer their blood glucose data from their home blood glucose meter to Rightest iFree CGM App. Meanwhile, medical specialists can monitor their database on the transmission of their data to provide accurate suggestions for their health without patients visiting the hospital in person during pandemics. Rightest iFree CGM App patients can receive informative articles and prompt responses from customer service when they have technical problems.

Bionime prioritizes patients’ personal data protection; therefore, Rightest iFree CGM App follows the HIPAA regulation led by the government to ensure safe practices in gathering, storing, and applications of patient information.

As for hospitalized patients, Rightest GM 700 Pro 2 is a point-of-care (POC) Blood Glucose monitoring system that personal BGM data can be integrated and transmitted via WIFI, Bluetooth, or Ethernet to Hospital Information System (HIS). With the help of the auto-coding function, Rightest GM 700 Pro 2 is able to eliminate the need for manual coding and delivery immediately accuracy. Also, a replaceable strip holder can avoid contamination caused by blood samples, bringing convenience to healthcare professionals due to its lightweight design and barcode scanner. Furthermore, Rightest GM 700 Pro 2 is certified and complies with the ISO 15197 guideline, CE marking, and TFDA international standard. GS 770 test strip reaching 10/10 accuracy standard measure by Rightest GM 700 Pro 2 compared with reference values from a YSI analyzer. As a result, all these ensure that Bionime can provide safe and accurate data in making the best treatment decision possible.

Founded in 2003, Bionime keeps with the goal of providing “Better health for More People”. Apart from providing ODM and OBM diabetes self-monitoring products, it has also integrated a technological approach in IoMT to ensure seamless and secure transmission of data between users and relevant concerned parties while using their products. As the Medical Things (IoMT) market offers significant growth opportunities in remote patient monitoring for all healthcare stakeholders and leading information and communication technology (ICT) companies, Bionime is dedicated to bringing better solutions for both healthcare professionals and diabetes patients.

Bionime sincerely invites specialists and executives who are interesting in a new trend of medical management in the face of pandemic conditions to participate in 2022 MEDICAL FAIR at Düsseldorf and visit the booth #B65 HALL 1 from 14 to 17 November 2022.

Contact Info:
Name: Bionime
Email: Send Email
Organization: Bionime
Website: https://bionime.com/

Release ID: 89083632

If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us. We will respond and rectify the situation in the next 8 hours.

Go Top